The Dako PD-L1 IHC 22C3 pharmDx Interpretation Training Program
The Dako PD-L1 IHC 22C3 pharmDx Interpretation Training Program uses in-depth content, engaging activities, and comprehensive cases to help you confidently:
- Understand the core principles of PD-L1 pathology.
- Learn the process for evaluating stained specimens for PD-L1 expression.
- Recognize confounding considerations that affect PD-L1 interpretation.
- Score images for PD-L1 expression across a variety of patient samples
Gastric or gastroesophageal junction (GEJ) adenocarcinoma
PD-L1 is a proven biomarker in Gastric or gastroesophageal junction (GEJ) adenoma. Learn how to evaluate and score PD-L1 expression using PD-L1 IHC 22C3 pharmDx and the Combined Positive Score (CPS).
Cervical cancer
PD-L1 is a proven biomarker in Cervical cancer. Learn how to evaluate and score PD-L1 expression using PD-L1 IHC 22C3 pharmDx and the Combined Positive Score (CPS).
Urothelial carcinoma
PD-L1 is a proven biomarker in Urothelial carcinoma. Learn how to evaluate and score PD-L1 expression using PD-L1 IHC 22C3 pharmDx and the Combined Positive Score (CPS).
Head and neck squamous cell carcinoma (HNSCC)
PD-L1 is a proven biomarker in head and neck squamous cell carcinoma (HNSCC). Learn how to evaluate and score PD-L1 expression using PD-L1 IHC 22C3 pharmDx and the Combined Positive Score (CPS).
Esophageal squamous cell carcinoma (ESCC)
PD-L1 is a proven biomarker in Esophageal squamous cell carcinoma (ESCC). Learn how to evaluate and score PD-L1 expression using PD-L1 IHC 22C3 pharmDx and the Combined Positive Score (CPS).